Invesdor Group

800,000 people a year walk into a building that sits on water. Allas Pool Helsinki opened in 2017 on an underused stretch of port - pools, saunas, food and live music on one floating block in the middle of the city. Nine years on it is part of ordinary life in Helsinki, and the group has been EBITDA-positive since 2021, with the margin rising from 9% in 2022 to 33% in 2025. And now, Nordic Urban is building four more. Stockholm in 2027, then Tallinn, Turku and Cardiff in 2028. This bond funds the development work that gets them there. It is the 𝐬𝐞𝐜𝐨𝐧𝐝 𝐫𝐨𝐮𝐧𝐝 under the same programme. The first raised €𝟏,𝟏𝟕𝟓,𝟐𝟓𝟎 𝐟𝐫𝐨𝐦 𝟓𝟔𝟏 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 in July. The terms: ▪ 𝟖.𝟕𝟓% 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭 𝐩.𝐚., paid quarterly ▪ 4-year term ▪ From €250 per bond Link in the comments.

𝐎𝐧𝐥𝐲 𝟑 𝐝𝐚𝐲𝐬 𝐥𝐞𝐟𝐭 𝐭𝐨 𝐢𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 Resonandina In Colombia, the law says a breast cancer case should be diagnosed and treatment started within 25 days. Bernardo Rendon G, who runs the oncology centre in Villavicencio, puts the reality at around 245 days nationally and about 275 in his own city. That gap is not mostly about doctors. It is about equipment. Latin America and the Caribbean have roughly 800 linear accelerators between them; more than 1,600 additional machines would be needed to reach benchmark coverage. 𝐓𝐡𝐢𝐬 𝐫𝐨𝐮𝐧𝐝 𝐟𝐮𝐧𝐝𝐬 𝐨𝐧𝐞 𝐨𝐟 𝐭𝐡𝐞𝐦 - a linear accelerator, a CT simulator and a mammograph for a partner clinic in Villavicencio. This is Resonandina’s 𝐧𝐢𝐧𝐭𝐡 𝐫𝐨𝐮𝐧𝐝 𝐨𝐧 𝐈𝐧𝐯𝐞𝐬𝐝𝐨𝐫. More than 𝟔,𝟎𝟎𝟎 𝐜𝐫𝐨𝐰𝐝 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 have backed the company across eight previous rounds since 2023, and every payment has been made on time. Around 16 machines are in use with 12 more signed, on 𝟐𝟎𝟐𝟓 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐨𝐟 𝐚𝐛𝐨𝐮𝐭 €𝟓.𝟐𝟖 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 - 21.5% above 2023 - and roughly €2.6 million EBITDA. 𝐓𝐡𝐞 𝐭𝐞𝐫𝐦𝐬:  ▪ 𝟗.𝟐𝟎% 𝐟𝐢𝐱𝐞𝐝 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭 𝐩𝐞𝐫 𝐲𝐞𝐚𝐫 ▪ 4-year term, interest and repayment every six months ▪ From €250 per bond ▪ 𝐑𝐨𝐮𝐧𝐝 𝐜𝐥𝐨𝐬𝐞𝐬 𝟏𝟗 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 Link in the comments.

𝐖𝐡𝐲 𝐅𝐢𝐧𝐥𝐚𝐧𝐝 𝐜𝐨𝐮𝐥𝐝 𝐛𝐞 𝐨𝐧𝐞 𝐨𝐟 𝐄𝐮𝐫𝐨𝐩𝐞’𝐬 𝐧𝐞𝐱𝐭 𝐝𝐚𝐭𝐚 𝐜𝐞𝐧𝐭𝐫𝐞 𝐡𝐨𝐭𝐬𝐩𝐨𝐭𝐬   Europe’s data centre landscape is changing fast. AI and cloud computing are driving demand for new infrastructure, but where that infrastructure is built matters.   Finland is emerging as an interesting market. Abundant low-carbon energy, a cool climate and strong digital infrastructure make the country well suited for data centre development. And as these projects grow, so does the need for the people and services that help build them.   That’s where Ahertaja Oy comes in. The Finnish company provides workforce and site-support services for large construction and data centre projects, putting it in a position to benefit from this growing market. 𝐓𝐨𝐝𝐚𝐲, 𝐰𝐞’𝐫𝐞 𝐥𝐚𝐮𝐧𝐜𝐡𝐢𝐧𝐠 𝐚 𝐧𝐞𝐰 𝐛𝐨𝐧𝐝 𝐩𝐫𝐨𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐀𝐡𝐞𝐫𝐭𝐚𝐣𝐚 𝐨𝐧 𝐈𝐧𝐯𝐞𝐬𝐝𝐨𝐫: → 7.25% interest p.a. → 1.5-year duration → €250 per bond   For investors, it’s an opportunity to invest in a company operating at the intersection of two major trends: Finland’s growing data centre market and Europe’s accelerating digital infrastructure needs. Investment link in the comments ↓

𝐓𝐡𝐫𝐞𝐞 𝐝𝐚𝐲𝐬 𝐥𝐞𝐟𝐭 𝐭𝐨 𝐢𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 Fibersail. Catch a problem in a wind turbine blade early and it is 𝐚 €𝟑𝟎,𝟎𝟎𝟎–€𝟓𝟎,𝟎𝟎𝟎 𝐫𝐞𝐩𝐚𝐢𝐫. Miss it, and the same blade can become a €𝟑–𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐟𝐚𝐢𝐥𝐮𝐫𝐞. Swipe to see what sits in between. That gap is the business. Fibersail's fibre-optic sensors measure the full shape of every blade, continuously, so damage shows up while it is still small - and still cheap to fix. €950,000 is already anchored in this round. 𝐓𝐡𝐫𝐞𝐞 𝐝𝐚𝐲𝐬 𝐭𝐨 𝐣𝐨𝐢𝐧 𝐭𝐡𝐞𝐦. 𝟏𝟑.𝟖𝟖-𝟐𝟏.𝟒𝟎% 𝐞𝐪𝐮𝐢𝐭𝐲 𝐨𝐟𝐟𝐞𝐫𝐞𝐝 · €𝟗 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐫𝐞-𝐦𝐨𝐧𝐞𝐲 𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 · Link in the comments. The round closes on 𝟓 𝐎𝐜𝐭𝐨𝐛𝐞𝐫.

86% of seizures that happen during sleep are never recorded. Not by the hospital - by the person having them. Neuro Event Labs Oy 𝐢𝐬 𝐥𝐢𝐯𝐞 𝐨𝐧 𝐈𝐧𝐯𝐞𝐬𝐝𝐨𝐫 𝐟𝐨𝐫 𝟗 𝐦𝐨𝐫𝐞 𝐝𝐚𝐲𝐬. "𝐀 𝐬𝐞𝐢𝐳𝐮𝐫𝐞 𝐈 𝐜𝐚𝐧'𝐭 𝐬𝐞𝐞 𝐢𝐬 𝐚 𝐬𝐞𝐢𝐳𝐮𝐫𝐞 𝐈 𝐜𝐚𝐧'𝐭 𝐭𝐫𝐞𝐚𝐭," says Professor Jukka Peltola, neurologist at Tampere University and co-founder of the company. For years, patients came to his appointments and tried to describe what had happened at home. From that, he had to work out what kind of seizure it was and what to do next. The research backs him up. When seizure diaries were checked against video-EEG, 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐡𝐚𝐥𝐟 𝐨𝐟 𝐚𝐥𝐥 𝐫𝐞𝐜𝐨𝐫𝐝𝐞𝐝 𝐬𝐞𝐢𝐳𝐮𝐫𝐞𝐬 had never been written down - not from forgetfulness, but because people are often unaware a seizure happened at all. Yet that count is what treatment runs on: whether a medication is switched, whether someone is referred for surgery, whether a person is cleared to drive. So 𝐍𝐞𝐥𝐥𝐢 𝐰𝐚𝐭𝐜𝐡𝐞𝐬 𝐢𝐧𝐬𝐭𝐞𝐚𝐝. A camera in the room, nothing on the patient's body, AI that detects seizures and turns weeks of nights into the reports Peltola never used to have. ✓ 𝐂𝐄-𝐦𝐚𝐫𝐤𝐞𝐝 in Europe, 𝐅𝐃𝐀-𝐜𝐥𝐞𝐚𝐫𝐞𝐝 for US hospitals ✓ 𝟕,𝟎𝟎𝟎+ patients across 𝟔𝟎+ hospitals ✓ €𝟏.𝟐𝐌 revenue in 2025 ✓ Backed by Hadean Ventures, Maki.vc and the EU's EIC Fund €𝟏𝟗.𝟔𝟐 per share · €𝟏𝟓𝐌 pre-money valuation · The round closes 𝟐 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 👉 Link in the comments.

For a MedTech company, regulatory clearance opens the door. Reimbursement gets them into hospitals.   Neuro Event Labs Oy now has both in the US - the world's largest healthcare market.   Nelli received FDA 510(k) clearance in November 2025. From 1 October 2026, US hospitals using it for eligible Medicare patients can also receive an additional payment under CMS's NTAP programme, covering part of the cost of adoption.   For investors, that's the milestone that opens a new market - and US expansion is exactly what this round is funding.   Congratulations to the Neuro Event Labs team, and thank you Hadean Ventures for sharing the news.   The round is open on Invesdor for 11 more days - link in the comments.

When the lead investor puts his own name behind a round, it says more than any pitch deck.   Skirderf Capital is Fibersail's largest shareholder, and Jan Fredriks sits on the supervisory board - so this is backing from someone who knows the company from the inside. The round is anchored with €950,000.   Fibersail measures the full shape of every wind turbine blade, continuously, using fibre-optic sensors. Blade damage that would otherwise be found at the next inspection shows up while it's still small.   Through Invesdor, our community can now join the same round - from €5.98 per share.   Thank you Jan Fredriks and the Skirderf team for opening this to a broader group of investors.   Link in the comments!

"𝐀 𝐬𝐞𝐢𝐳𝐮𝐫𝐞 𝐈 𝐜𝐚𝐧'𝐭 𝐬𝐞𝐞 𝐢𝐬 𝐚 𝐬𝐞𝐢𝐳𝐮𝐫𝐞 𝐈 𝐜𝐚𝐧'𝐭 𝐭𝐫𝐞𝐚𝐭." That's Professor Jukka Peltola, 𝐧𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐬𝐭 𝐚𝐭 𝐓𝐚𝐦𝐩𝐞𝐫𝐞 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲, describing the problem he ran into for years. Patients would come to an appointment and try to describe what had happened at home. From that, he had to work out what kind of seizure it was and what to do next. 𝐍𝐞𝐥𝐥𝐢 was built to answer that: a camera above the bed, AI that detects and classifies motor seizures, and objective reports from where seizures actually happen - at home, at night, when no clinician is watching. Nine years on, this is no longer a question of whether the technology works. - 𝟕,𝟎𝟎𝟎+ 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 studied across 60+ hospitals in 10 countries - MDR Class IIa in Europe, FDA clearance in the US - An independent NHS-funded study found average savings of about €𝟓𝟎𝟎 𝐩𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 - A positive CMS decision means US hospitals can 𝐫𝐞𝐜𝐞𝐢𝐯𝐞 𝐮𝐩 𝐭𝐨 $𝟗𝟕𝟓 𝐩𝐞𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 Dr Rhys Thomas in Newcastle, who has now 𝐬𝐭𝐮𝐝𝐢𝐞𝐝 𝟐𝟎 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐍𝐞𝐥𝐥𝐢, says that having offered patients accurate recording at home, it would be very hard to go back and offer less. Neuro Event Labs Oy has spent nine years and roughly €𝟏𝟐.𝟐 𝐦𝐢𝐥𝐥𝐢𝐨𝐧  building the evidence, the clearances and the dataset. This round funds what comes next. 𝐓𝐡𝐞 𝐫𝐨𝐮𝐧𝐝 𝐚𝐭 𝐚 𝐠𝐥𝐚𝐧𝐜𝐞  - €𝟏𝟓𝐦 𝐩𝐫𝐞-𝐦𝐨𝐧𝐞𝐲 𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧, reported by the company - below its 2024 post-money of approximately €17.7m - Led by @Hadean Ventures with €𝟓𝟎𝟎,𝟎𝟎𝟎 in anchor commitments - €𝟏𝟗.𝟔𝟐 𝐩𝐞𝐫 𝐬𝐡𝐚𝐫𝐞 - Closes 𝟐𝟏 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 Invest via the link in the comments.

𝐅𝐢𝐯𝐞 𝐧𝐢𝐠𝐡𝐭𝐬 𝐢𝐧 𝐡𝐨𝐬𝐩𝐢𝐭𝐚𝐥. 𝐎𝐫 𝟐𝟖 𝐧𝐢𝐠𝐡𝐭𝐬 𝐚𝐭 𝐡𝐨𝐦𝐞. Martta is 21. She was diagnosed with epilepsy at four, which means she has lived with it for seventeen years - and for most of that time, her seizures happened at night, when nobody could see them.   The standard way to find out what happens overnight is video-EEG monitoring in hospital. It captures roughly five days and nights. Her mother Taina describes the alternative they used instead: a camera system at home, recording for 28 nights. Delivered, installed, and collected again from their door. No hospital stay, no wires, no disruption to normal life.   With 28 nights of data instead of five, Martta's doctors could see what was actually happening. They found a targeted medication that reduced and controlled her nocturnal seizures.   That's the difference better data makes: not a new drug, but the right one.   The system is called 𝐍𝐞𝐥𝐥𝐢, built by Neuro Event Labs Oy in Tampere. It's CE-marked, used with more than 7,000 patients across 60+ hospitals, and trained on over a million hours of clinically annotated data.   𝐍𝐞𝐮𝐫𝐨 𝐄𝐯𝐞𝐧𝐭 𝐋𝐚𝐛𝐬 𝐢𝐬 𝐜𝐮𝐫𝐫𝐞𝐧𝐭𝐥𝐲 𝐥𝐢𝐯𝐞 𝐨𝐧 𝐈𝐧𝐯𝐞𝐬𝐝𝐨𝐫.   €19.62 per share · €15 million pre-money valuation ·    👉 Link to the investment opportunity in the comments.   As Taina puts it, advancing epilepsy research matters so that young adults like Martta can live a good life despite the diagnosis.